RxDoctor Payments Data

Miguel Ariza, MD

Internal Medicine · Dracut, MANPI 1104850858

Payments from drug & device makers

$48,521in general payments, 2019–2025

Across 51 payments — averaging $951.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$48K
  • Lilly USA, LLC$189
  • Amgen$133
  • Novo Nordisk$132
  • Abbott$59
  • Bayer$57
  • plus $388 from 11 others

What the payments were for

  • Food & beverage$958100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$48,521 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$116,496
Medicare patients
557
Services billed
1,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide804$1,071,020
OzempicSemaglutide821$1,063,880
MounjaroTirzepatide807$952,310
JardianceEmpagliflozin471$676,610
FarxigaDapagliflozin Propanediol145$184,688
JanuviaSitagliptin Phosphate83$118,410
ProliaDenosumab67$111,980
RybelsusSemaglutide81$92,132
Tresiba Flextouch U-200Insulin Degludec60$84,011
TradjentaLinagliptin80$77,106
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog72$57,681
Tresiba Flextouch U-100Insulin Degludec64$43,389
SynjardyEmpagliflozin/Metformin Hcl14$24,039
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog61$23,284
Humalog Mix 50-50 KwikpenInsulin Lispro Protamin/Lispro61$22,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$189$2,023,3301,611 claims
Novo NordiskOzempic, Rybelsus$132$1,156,012902 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$29$777,755565 claims
AmgenProlia$133$111,98067 claims
AbbVieSynthroid$47,564$3,23949 claims
Sanofi-aventis U.S. LLCLantus$26$2,81819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Dracut

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →